Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
AXGNthis companyAxoGen, Inc.	$50.40	-96.26×	11.7×	6.69×	8,017.22×	-145.4%	74.3%	-3.5%	-7.0%	-12.2%	-3.9%	-0.2%	0.52×	167.09×	-1.02×	5.11×	0.0%	4	33.22	2	C
BSEMBioStem Technologies, Inc.	$1.16	-9.77×	1.63×	1.34×	-121.76×	-13121.0%	93.1%	-1.5%	-13.9%	-16.8%	-1.6%	10.3%	0.09×	85.09×	0×	4.12×	0.0%	2	-3.33	2	C
HUMAHumacyte, Inc.	$0.47	-3.69×	48.86×	74.54×	-7.48×	-105.8%	-736.5%	-5271.7%	-2003.6%	-1313.4%	-107.0%	-69.7%	20.86×	-0.65×	-9.55×	3.69×	0.0%	3	-8.67	1	D+
MDXGMiMedx Group, Inc.	$3.26	20.52×	3.9×	2.39×	10.33×	13.9%	82.6%	15.3%	11.6%	18.9%	16.7%	7.3%	0.09×	-1.73×	35.83×	4.32×	0.0%	4	6.57	2	C
ORGOOrganogenesis Holdings Inc.	$0.82	32.38×	1.51×	1.17×	9.41×	422.9%	75.6%	9.9%	6.6%	8.5%	8.5%	-3.7%	0.31×	0.53×	0×	3.62×	0.0%	2	1.23	2	C+
TELATELA Bio, Inc.	$0.91	-1.42×	8.78×	0.69×	-1.86×	61.9%	67.7%	-42.0%	-48.4%	-615.1%	-53.2%	-51.7%	8.82×	-0.15×	-6.44×	4.2×	0.0%	3	-9.39	2	B-
Peer median	—	-1.42×	3.9×	1.34×	-1.86×	13.9%	75.6%	-1.5%	-13.9%	-16.8%	-1.6%	-3.7%	0.31×	-0.15×	0×	4.12×	0.0%	3	-3.33	2	—